ADENOCOR

This brand name is authorized in Estonia, Ireland, Lithuania, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, UK.

Active ingredients

The drug ADENOCOR contains one active pharmaceutical ingredient (API):

1	Adenine Deoxy Nucleoside UNII K72T3FS567 - ADENOSINE
	Adenosine is a purine nucleoside which is present in all cells of the body. Animal pharmacology studies have in several species shown that adenosine has a negative dromotropic effect on the atrioventricular (AV) node.
	Read more about Adenine Deoxy Nucleoside

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADENOCOR Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01EB10	Adenosine	C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations
Discover more medicines within C01EB10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1008391
ES	Centro de información online de medicamentos de la AEMPS	60375
GB	Medicines & Healthcare Products Regulatory Agency	47447
LT	Valstybinė vaistų kontrolės tarnyba	1090482, 1090617
NL	Z-Index G-Standaard	13822764
NL	Z-Index G-Standaard, PRK	39292
NZ	Medicines and Medical Devices Safety Authority	7021
PL	Rejestru Produktów Leczniczych	100002987, 100291980, 100346876, 100371489, 100424027, 100429645
SG	Health Sciences Authority	07679P
ZA	Health Products Regulatory Authority	27/6.2/0467